Resources

Publications

 

 

Show All

February 2013

Jehle J, Ficker E, Wan X, Deschenes I, Kisselbach J, Wiedmann F, Staudacher I, Schmidt C, Schweizer PA, Becker R, Katus HA, and Thomas D

Mechanisms of Zolpidem-induced Long QT Syndrome: Acute Inhibition of Recombinant hERG K+ Channels and Action Potential Prolongation in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells

Br J Pharmacol 168(5):1215-29

Publication Date: February 21, 2013

Product Type: iCell Cardiomyocytes

Summary:

iCell Cardiomyocytes exhibited prolongation of cardiac action potential duration in response to zolpidem, a short-acting hypnotic drug prescribed to treat insomnia that has been clinically associated with acquired long QT syndrome (LQTS) and torsade de pointes (TdP).

Impact:

iCell Cardiomyocytes treated with a known toxic drug compound showed biochemical responses that mimic toxic responses observed in the clinic, demonstrating that iCell Cardiomyocytes are a relevant in vitro model to predict human cardiotoxicity.